Open Nav

Please submit your session questions in advance.

Filtered by:

Clear All
Tuesday, October 22
8:30am The Next Wave of Cancer Therapies: Allogeneic Cell Therapies and Other Pioneers Benjamin Cowen, ImmuoMet Therapeutics; Kanya Rajangam, Nkarta Therapeutics show more Session Description As the industry continues to do revolutionary research on cancer, a host of new treatment options for therapies are showing promising data to disrupt the spread of tumors and inching us closer to a world where cancers can be cured. This panel reviews emerging treatment options in cancer, including the next wave of CAR-T, NK cell, and other pioneering approaches, highlighting promises enabled by each and the challenges to be resolved on the path to approvals and helping patients worldwide. Time Tuesday, Oct 22 8:30AM - 9:40AM Location California East Speakers Benjamin Cowen ImmuoMet Therapeutics Kanya Rajangam Nkarta Therapeutics
9:45am Private Investors' Incubators for University-Sourced Ideas Julie Gilmore, Eli Lilly and Company; Kevin Grimes, Stanford University; Satish Jindal, BioMotiv show more Session Description Recognizing a persistent “valley of death” in funding for medical research past the government-grant stage, several organizations have recently launched specialized investment vehicles. These vehicles are specifically designed to support translational research for university-sourced ideas to become independent companies capable of moving biological ideas into human drug development and to attract conventional venture investors. Hear from investors, academics, and entrepreneurs pursuing these new approaches that resolve critical bottlenecks as they work to lower initial project risks and accelerate progress through proof-of-concept. Time Tuesday, Oct 22 9:45AM - 10:40AM Location California East Speakers Julie Gilmore Eli Lilly and Company Kevin Grimes Stanford University Satish Jindal BioMotiv
10:45am Gene Therapies: The Pipeline Towards a New Era for Patients show more Session Description Gene therapies have the potential to increase the healthspan of patients and offer new approaches to treating diseases, with a sizable pipeline in development. Early leaders in the field have focused on rare diseases which continues to open the pathway for other treatments in oncology and infectious and chronic diseases. Attend this session to hear about successful approaches, challenges in protein delivery, and the future of expanding this class of medicines. Time Tuesday, Oct 22 10:45AM - 11:40AM Location California East
12:00pm Policy Outlook-Implications of the U.S. Government's Policies on Biotech Investment from China show more Session Description According to Pitchbook, Chinese venture capital investment in U.S. biotechs has declined more than 60% in the first half of 2019. The increased review of the Committee on Foreign Investment in the US (CFIUS) on transactions, national security concerns, and trade negotiations have created a new landscape for cross-border business. The session will explore how biotech companies can continue to raise capital, the proposed rulemaking from CFIUS in the coming months, and a pathway for companies to remain innovative while CEOs and investors navigate these changes. Time Tuesday, Oct 22 12:00PM - 1:25PM
2:00pm Fireside Chat: Jean-Jacques Bienaimé, Chairman and CEO, BioMarin Jean-Jacques Bienaimé, BioMarin show more Session Description . Time Tuesday, Oct 22 2:00PM - 2:55PM Speakers Jean-Jacques Bienaimé BioMarin
3:00pm Recruiting Talent to Meet Corporate Board Requirements and Representation Goals show more Session Description By the end of 2019, publicly traded companies in California must have at least one woman director and those targets will increase by 2021. Massachusetts, Pennsylvania, and New Jersey along with other states have considered similar targets which will impact the biotechnology industry. As start-ups and small and medium sized biotech companies consider company growth and future exits, starting early with inclusive hiring practices and board recruitment has become a business priority. Attend this session to gain insight on corporate governance best practices and tips on conducting searches for companies to remain innovative and competitive in this changing environment. Resources for leadership teams and boards will be shared including tools created as part of BIO’s recently launched "Right Mix Matters" campaign. Time Tuesday, Oct 22 3:00PM - 3:55PM Location California East
4:00pm View from the Board: To IPO Now or Not? show more Session Description With uncertain market conditions and concerns about realistic valuation expectations, innovative biotechs are trying to pinpoint the right time to go public. The right executive team and a clear, strategic roadmap have become more imperative as companies continually receive mixed signals from potential bookrunners and concerns are raised over IP in course of making a compelling case for going public and gaining access to capital markets. This panel will review how to structure those conversations and decisions around the current landscape and be as productive as possible toward timing the market accurately for a future IPO. Time Tuesday, Oct 22 4:00PM - 4:55PM
Wednesday, October 23
8:30am Progress in CNS Drug Development Outside Neurodegeneration show more Session Description Recent studies from the National MS Society have estimated that nearly one million people in the United States are suffering from Multiple Sclerosis. Another thirty thousand suffer from ALS, and thousands more from other CNS disorders that remain without a cure. In order to address the unmet medical needs of this patient population, dozens of companies from across the biotechnology industry are involved in late-phase clinical trials that are exploring the efficacy of different drug treatments on a variety of CNS disorders. On the investment side of the equation, neurology companies had the third highest number of biopharma deals in the first half of 2019, with over $800 million invested, according to the Silicon Valley Bank Mid-Year Report 2019. Hear from researchers and biotech executives involved in CNS drug development to gain insight into how the industry is expanding and the current clinical trials that have the potential to provide life-changing therapeutic solutions. Time Wednesday, Oct 23 8:30AM - 9:40AM Location California East
9:45am Advice on Pitching to Family Offices, Venture Philanthropies, and Other Non-Private Equity Funding Sources show more Session Description With investment on the rise and the biotechnology industry continuously providing enormous reward opportunities, the demographic of investors has started to shift from the typical stakeholder. How should CEOs approach these potential partners and successfully secure a funding round? This session will feature experienced voices explaining the strategies to employ to properly satisfy a potential investor’s expectation and secure the desired capital. Time Wednesday, Oct 23 9:45AM - 10:40AM Location California East
10:45am Molecular Diagnostics: Drivers of New Investor Interest and Reimbursement Success show more Session Description As the biotechnology industry continues to address unmet medical needs across a wide variety of diseases and disorders, emerging innovative diagnostics methods are paving the way for earlier detection and increased levels of response to treatment. Companion and molecular diagnostics offer advanced methods of identifying biomarkers for cancer and other diseases and allow for the application of bespoke immune-based therapies. Additionally, Diagnostics Analytics deals spiked in the first half of 2019, with 119 deals totaling $2.164 billion, and are predicted to continue a three-year upward trend, according to the Silicon Valley Bank Mid-Year Report 2019. This panel explores the novel drug and product development from diagnostics companies in the industry that drive funding and reimbursement. Time Wednesday, Oct 23 10:45AM - 11:40AM Location California East
12:00pm Fireside Chat: Wende Hutton, General Partner, Canaan Wende Hutton, Canaan show more Session Description . Time Wednesday, Oct 23 12:00PM - 1:25PM Location Grand Ballroom Speakers Wende Hutton Canaan
1:45pm Separating Artificial Intelligence Hype from Real Utility in Drug Development show more Session Description Recent data shows venture investment in AI-focused biopharma companies reached a new high of $1.4B through the first half of this year, according to CB Insights. However, the wide variance in applications and algorithms has complicated the ability to map progress in drug development techniques. As leaders in this space now begin to point to molecules moving into development and early clinical results, the prioritization of tools for other biotechs to consider adopting becomes clearer. This session will examine where AI can improve current drug discovery and development versus technological promises that are still years away from delivery. Time Wednesday, Oct 23 1:45PM - 2:40PM Location California East
2:45pm Best Practices in Biopharma Alliances with Digital Therapeutics Partners show more Session Description As the FDA has standardized the approval pathway for digital therapeutics, an increasing number of such therapies are reaching patients, often in collaboration with existing biopharma companies. Rock Health released an in-depth study earlier this year identifying four success factors that must be shared for such partnerships: value proposition of the project, organizational commitment, evidence standards, and channel strategy with business model. This session will feature Rock Health’s specific data then discuss the opportunities and challenges with digital therapeutics and biopharma alliance partners themselves. Time Wednesday, Oct 23 2:45PM - 3:55PM Location California East
4:00pm Market Outlook-Taking the Temperature of the IPO Market in an Era of Large Pharma M&A show more Session Description As we start to close out 2019, the mixed signals regarding the appetite for IPOs are off from 2018’s strong finish. This year’s 33 offerings in the 1H have totaled $2.992 billion, compared to the $3.484 billion seen in the 35 offerings from last year. Large pharma M&A deals, however, continue to surprise and raise questions about a temporary market shift or a lasting trend. With market volatility also on the rise aided by continued global trade tensions, the second half of 2019 raises concerns about the endurance of high valuations. This session will examine the path forward while highlighting the availability of quality targets in the market. Time Wednesday, Oct 23 4:00PM - 4:55PM Location California East
No time slot
360Medlink Jean-Manasse Theagene, 360Medlink show more Speakers Jean-Manasse Theagene 360Medlink Abalone Bio, Inc. Richard Yu, Abalone Bio, Inc show more Speakers Richard Yu Abalone Bio, Inc Abreos Biosciences, Inc. Bradley Messmer, Abreos Biosciences show more Speakers Bradley Messmer Abreos Biosciences Accuitis, Inc. Rick Coulon, Accuitis, Inc. show more Speakers Rick Coulon Accuitis, Inc. Acquist Therapeutics, Inc. Ray Warrell, Acquist Therapeutics, Inc. show more Speakers Ray Warrell Acquist Therapeutics, Inc. ACT Genomics Shu-Jen Chen, ACT Genomics Co., Ltd. show more Speakers Shu-Jen Chen ACT Genomics Co., Ltd. Actinium Pharmaceuticals, Inc. Sandesh Seth, Actinium Pharmaceuticals, Inc. show more Speakers Sandesh Seth Actinium Pharmaceuticals, Inc. ActoBio Therapeutics, Inc. Pieter Rottiers, ActoBio Therapeutics, Inc. show more Speakers Pieter Rottiers ActoBio Therapeutics, Inc. Adjuvance Technologies Inc. Tyler Martin, Adjuvance Technologies show more Speakers Tyler Martin Adjuvance Technologies Aethlon Medical, Inc. Timothy Rodell, Aethlon Medical, Inc. show more Speakers Timothy Rodell Aethlon Medical, Inc. AIVITA Biomedical Hans Keirstead, AIVITA Biomedical show more Speakers Hans Keirstead AIVITA Biomedical Altimmune Inc. Vipin Garg, Altimmune Inc. show more Speakers Vipin Garg Altimmune Inc. American Gene Technologies Norman Rogers, American Gene Technologies show more Speakers Norman Rogers American Gene Technologies Amygdala Neurosciences Peter Strumph, Amygdala Neurosciences Inc. show more Speakers Peter Strumph Amygdala Neurosciences Inc. Anima Biotech Inc. Yochi Slonim, Anima Biotech Inc. show more Speakers Yochi Slonim Anima Biotech Inc. Antidote Laurent Schockmel, Antidote show more Speakers Laurent Schockmel Antidote Arcturus Therapeutics Joseph Payne, Arcturus Therapeutics show more Speakers Joseph Payne Arcturus Therapeutics Aristea Therapeutics James Mackay, Aristea Therapeutics show more Speakers James Mackay Aristea Therapeutics Attentive Therapeutics Michael Reilly, Attentive Therapeutics show more Speakers Michael Reilly Attentive Therapeutics Avro Life Science Shak Lakhani, Avro Life Science show more Speakers Shak Lakhani Avro Life Science AxeroVision, Inc. Achim Krauss, AxeroVision, Inc. show more Speakers Achim Krauss AxeroVision, Inc. Azure8 Vipula Tailor, Azure8 show more Speakers Vipula Tailor Azure8 BioMarker Strategies, LLC Jerry Parrott, BioMarker Strategies, LLC show more Speakers Jerry Parrott BioMarker Strategies, LLC BioTrillion Savan Devani, BioTrillion show more Speakers Savan Devani BioTrillion BioXcel Therapeutics Vimal Mehta, BioXcel Therapeutics show more Speakers Vimal Mehta BioXcel Therapeutics Bipharm LLC Andrey Boldyrev, Bipharm show more Speakers Andrey Boldyrev Bipharm Bird Rock Bio. Inc. Paul Grayson, Bird Rock Bio Inc. show more Speakers Paul Grayson Bird Rock Bio Inc. Boundless Bio, Inc. Zachary Hornby, Boundless Bio, Inc. show more Speakers Zachary Hornby Boundless Bio, Inc. Brava Diagnostics, Inc. Byron Hewett, Brava Diagnostics, Inc. show more Speakers Byron Hewett Brava Diagnostics, Inc. BridGene Biosciences, Inc. Ping Cao, BridGene Biosciences, Inc. show more Speakers Ping Cao BridGene Biosciences, Inc. Cantabio Pharmaceuticals Gergely Toth, Cantabio Pharmaceuticals show more Speakers Gergely Toth Cantabio Pharmaceuticals Caribou Biosciences Timothy Herpin, Caribou Biosciences show more Speakers Timothy Herpin Caribou Biosciences Carmell Therapeutics Randy Hubbell, Carmell Therapeutics show more Speakers Randy Hubbell Carmell Therapeutics Cellintec Cheryl Cathey, Cellintec show more Speakers Cheryl Cathey Cellintec Cerevance, Inc. Brad Margus, Cerevance, Inc. show more Speakers Brad Margus Cerevance, Inc. CerSci Therapeutics Lucas Rodriguez, CerSci Therapeutics show more Speakers Lucas Rodriguez CerSci Therapeutics Cesca Therapeutics Inc. Chris Xu, Cesca Therapeutics Inc. show more Speakers Chris Xu Cesca Therapeutics Inc. Circumvent Andrew Lim, Circumvent show more Speakers Andrew Lim Circumvent Clara Biotech James West, Clara Biotech Inc. show more Speakers James West Clara Biotech Inc. CohBar Steven Engle, CohBar show more Speakers Steven Engle CohBar Cytonus Therapeutics Inc. Remo Moomiaie-Qajar, Cytonus Therapeutics Inc. show more Speakers Remo Moomiaie-Qajar Cytonus Therapeutics Inc. Daré Bioscience Sabrina Johnson, Daré Bioscience, Inc. show more Speakers Sabrina Johnson Daré Bioscience, Inc. Deep Lens, Inc. Simon Arkell, Deep Lens, Inc. show more Speakers Simon Arkell Deep Lens, Inc. DotBio Pte. Ltd. Ignacio Asial, DotBio Pte. Ltd. show more Speakers Ignacio Asial DotBio Pte. Ltd. Drusolv Therapeutics John Edwards, Drusolv Therapeutics show more Speakers John Edwards Drusolv Therapeutics Dyve Biosciences Ryan Beal, Dyve Biosciences show more Speakers Ryan Beal Dyve Biosciences Elex Biotech, Inc. Douglas Kawahara, Elex Biotech, Inc. show more Speakers Douglas Kawahara Elex Biotech, Inc. Engine Biosciences Jeffrey Lu, Engine Biosciences show more Speakers Jeffrey Lu Engine Biosciences Ensysce Biosciences, Inc. Lynn Kirkpatrick, Ensysce Biosciences Inc show more Speakers Lynn Kirkpatrick Ensysce Biosciences Inc Epilepsy Foundation Sonya Dumanis, Epilepsy Foundation show more Speakers Sonya Dumanis Epilepsy Foundation Ethris GmbH Gita Dittmar, Ethris GmbH show more Speakers Gita Dittmar Ethris GmbH Exicure David Giljohann, Exicure show more Speakers David Giljohann Exicure FenoLogica Biosciences, Inc. Sean MacLeod, FenoLogica Biosciences, Inc. show more Speakers Sean MacLeod FenoLogica Biosciences, Inc. Fibrocell Science John Maslowski, Fibrocell Science show more Speakers John Maslowski Fibrocell Science First Light Diagnostics David Macdonald, First Light Diagnostics show more Speakers David Macdonald First Light Diagnostics GLAdiator Biosciences Terry Hermiston, GLAdiator Biosciences show more Speakers Terry Hermiston GLAdiator Biosciences Golden Biotechnology Corp. Today Su, Golden Biotechnology Corp. show more Speakers Today Su Golden Biotechnology Corp. Greenwich LifeSciences Snehal Patel, Greenwich LifeSciences show more Speakers Snehal Patel Greenwich LifeSciences Haystack Sciences Jonathan Burbaum, Haystack Sciences show more Speakers Jonathan Burbaum Haystack Sciences Heartseed Inc. Kikuo Yasui, Heartseed Inc. show more Speakers Kikuo Yasui Heartseed Inc. Histogen Inc. Richard Pascoe, Histogen Inc. show more Speakers Richard Pascoe Histogen Inc. IBI Thomas Reeves, IBI show more Speakers Thomas Reeves IBI Ilya Pharma Evelina Vågesjö, Ilya Pharma show more Speakers Evelina Vågesjö Ilya Pharma ImmunoMet Therapeutics Benjamin Cowen, ImmuoMet Therapeutics show more Speakers Benjamin Cowen ImmuoMet Therapeutics Impact Therapeutics Jun Bao, Impact Therapeutics show more Speakers Jun Bao Impact Therapeutics IMV Inc. Frederic Ors, IMV Inc. show more Speakers Frederic Ors IMV Inc. Incysus Therapeutics, Inc. William Ho, Incysus Therapeutics, Inc. show more Speakers William Ho Incysus Therapeutics, Inc. Innovate Biopharmaceuticals, Inc. Jay Madan, Innovate Biopharmaceuticals, Inc. show more Speakers Jay Madan Innovate Biopharmaceuticals, Inc. Inquisatex Epitherapeutics Steven Holshouser, Inquisatex Eptitherapeutics show more Speakers Steven Holshouser Inquisatex Eptitherapeutics Intabio Lena Wu, Intabio show more Speakers Lena Wu Intabio InterVenn Biosciences Aldo Carrascoso, InterVenn Biosciences show more Speakers Aldo Carrascoso InterVenn Biosciences InvivoSciences Inc. Ayla Annac, InvivoSciences Inc. show more Speakers Ayla Annac InvivoSciences Inc. iPill Dispenser john Hsu, ipill dispesnser show more Speakers john Hsu ipill dispesnser ISOThrive LLC Jack Oswald, ISOThrive LLC show more Speakers Jack Oswald ISOThrive LLC Jaan Biotherapeutics LLC Bhawanjit Brar, Jaan Biotherapeutics LLC show more Speakers Bhawanjit Brar Jaan Biotherapeutics LLC Kineta, Inc. Shawn Iadonato, Kineta, Inc. show more Speakers Shawn Iadonato Kineta, Inc. Kleo Pharmaceuticals Doug Manion, Kleo Pharmaceuticals show more Speakers Doug Manion Kleo Pharmaceuticals Landos Biopharma Josep Bassaganya-Riera, Landos Biopharma show more Speakers Josep Bassaganya-Riera Landos Biopharma Leidos James Pannucci, Leidos show more Speakers James Pannucci Leidos Lung Therapeutics Brian Windsor, Lung Therapeutics show more Speakers Brian Windsor Lung Therapeutics MAIA Biotechnology, Inc. Joe Dillon, MAIA Biotechnology, Inc. show more Speakers Joe Dillon MAIA Biotechnology, Inc. Mantra Bio Alex Mok, Mantra Bio show more Speakers Alex Mok Mantra Bio Membio Shane Kilpatrick, Membio show more Speakers Shane Kilpatrick Membio Molecular Theranostics, LLC Yajuan Li, Molecular Theranostics, LLC show more Speakers Yajuan Li Molecular Theranostics, LLC Nammi Therapeutics, Inc. David Stover, Nammi Therapeutics, Inc. show more Speakers David Stover Nammi Therapeutics, Inc. NanoMed Targeting Systems Inc. Alex Harel, NanoMed Targeting Systems Inc. show more Speakers Alex Harel NanoMed Targeting Systems Inc. Nanostics Inc John Lewis, Nanostics Inc show more Speakers John Lewis Nanostics Inc NaNotics, LLC Lou Hawthorne, NaNotics, LLC show more Speakers Lou Hawthorne NaNotics, LLC NB Health Laboratory Co., Ltd Kiyoshi Takayama, NB Health Laboratory show more Speakers Kiyoshi Takayama NB Health Laboratory NeOnc Technologies Inc Thomas Chen , NeOnc Technologies Inc show more Speakers Thomas Chen NeOnc Technologies Inc Neumentum, Inc. Scott Shively, Neumentum, Inc. show more Speakers Scott Shively Neumentum, Inc. NeuroBo Pharmaceuticals John L. Brooks, NeuroBo Pharmaceuticals show more Speakers John L. Brooks NeuroBo Pharmaceuticals NeuroScientific Biopharmaceuticals Ltd Matt Liddelow, NeuroScientific Biopharmaceuticals Ltd show more Speakers Matt Liddelow NeuroScientific Biopharmaceuticals Ltd Novadip Biosciences Jeff Abbey, Novadip Biosciences show more Speakers Jeff Abbey Novadip Biosciences Nurix Therapeutics, Inc. Arthur Sands, Nurix Therapeutics, Inc. show more Speakers Arthur Sands Nurix Therapeutics, Inc. Oncolytics Biotech Inc. Matthew Coffey, Oncolytics Biotech Inc. show more Speakers Matthew Coffey Oncolytics Biotech Inc. OncoSenX Matthew Scholz, OncoSenX show more Speakers Matthew Scholz OncoSenX Orig3n, Inc. Robin Smith, Orig3n, Inc. show more Speakers Robin Smith Orig3n, Inc. Orion Biotechnology Canada Ian McGowan, Orion Biotechnology show more Speakers Ian McGowan Orion Biotechnology OxSonics Therapeutics Colin Story, OxSonics Therapeutics show more Speakers Colin Story OxSonics Therapeutics Pacylex Pharmaceuticals, Inc. Michael Weickert, Pacylex Pharmaceuticals, Inc. show more Speakers Michael Weickert Pacylex Pharmaceuticals, Inc. Phanes Therapeutics, Inc. Ming Wang, Phanes Therapeutics show more Speakers Ming Wang Phanes Therapeutics Phosplatin Therapeutics Robert Fallon, Phosplatin Therapeutics show more Speakers Robert Fallon Phosplatin Therapeutics Rakuten Medical Abhijit Bhatia, Rakuten Medical show more Speakers Abhijit Bhatia Rakuten Medical Ramot Inbal Landsberg, Ramot show more Speakers Inbal Landsberg Ramot RCE Technologies, Inc. Atandra Burman, RCE Technologies, Inc. show more Speakers Atandra Burman RCE Technologies, Inc. Resverlogix Corp. Donald McCaffrey, Resverlogix Corp. show more Speakers Donald McCaffrey Resverlogix Corp. Riptide Bioscience, Inc. Charles Garvin, Riptide Bioscience, Inc. show more Speakers Charles Garvin Riptide Bioscience, Inc. RubrYc Therapeutics, Inc. Isaac Brigth, RubrYc Therapeutics, Inc. show more Speakers Isaac Brigth RubrYc Therapeutics, Inc. Sapience Therapeutics, Inc. Barry Kappel, Sapience Therapeutics show more Speakers Barry Kappel Sapience Therapeutics Satellos Bioscience Inc. Frank Gleeson, Satellos Bioscience Inc. show more Speakers Frank Gleeson Satellos Bioscience Inc. Savanamed Ignacio H. Medrano, Savanamed show more Speakers Ignacio H. Medrano Savanamed SCA Robotics Rob Rao, SCA Robotics show more Speakers Rob Rao SCA Robotics SciBac Inc. Jeanette Mucha, SciBac Inc. show more Speakers Jeanette Mucha SciBac Inc. Senti Biosciences Timothy Lu, Senti Biosciences show more Speakers Timothy Lu Senti Biosciences Sentien Biotechnologies, Inc. Brian Miller, Sentien Biotechnologies, Inc. show more Speakers Brian Miller Sentien Biotechnologies, Inc. Serimmune, Inc. Noah Nasser, Serimmune, Inc. show more Speakers Noah Nasser Serimmune, Inc. SFA Therapeutics Ira Spector, SFA Therapeutics show more Speakers Ira Spector SFA Therapeutics Shifa Biomedical Corporation Sherin Abdel-Meguid, Shifa Biomedical Corporation show more Speakers Sherin Abdel-Meguid Shifa Biomedical Corporation SHINKEI Therapeutics GP Singh, SHINKEI Therapeutics show more Speakers GP Singh SHINKEI Therapeutics SmartPharm Therapeutics Jose Trevejo, SmartPharm Therapeutics show more Speakers Jose Trevejo SmartPharm Therapeutics Spheryx, Inc. Laura Philips, Spheryx, Inc. show more Speakers Laura Philips Spheryx, Inc. SpinalCyte Pete OHeeron, SpinalCyte, LLC show more Speakers Pete OHeeron SpinalCyte, LLC Splash Pharmaceuticals, Inc. David Nelson, Splash Pharmaceuticals show more Speakers David Nelson Splash Pharmaceuticals Summit Therapeutics Glyn Edwards, Summit Therapeutics show more Speakers Glyn Edwards Summit Therapeutics Synthetic Biologics, Inc. Steven Shallcross, Synthetic Biologics, Inc. show more Speakers Steven Shallcross Synthetic Biologics, Inc. Tempo Therapeutics Westbrook Weaver, Tempo Therapeutics, Inc show more Speakers Westbrook Weaver Tempo Therapeutics, Inc TheraTarget C. Matthew Peterson, TheraTarget show more Speakers C. Matthew Peterson TheraTarget Thousandoaks Biopharmaceuticals, Inc. Shun Luo, Thousand Oaks Biopharmaceuticals, Inc. show more Speakers Shun Luo Thousand Oaks Biopharmaceuticals, Inc. ThromboTherapeutics Inc. Michael Chapman, ThromboTherapeutics Inc. show more Speakers Michael Chapman ThromboTherapeutics Inc. Tierra Biosciences Zachary Sun, Tierra Biosciences show more Speakers Zachary Sun Tierra Biosciences Univfy Mylene Yao, Univfy show more Speakers Mylene Yao Univfy Verum Diagnostics Inc Victor Voroteliak, Verum Diagnostics Inc show more Speakers Victor Voroteliak Verum Diagnostics Inc Vigeo Therapeutics, Inc. Jing Watnick, Vigeo Therapeutics, Inc. show more Speakers Jing Watnick Vigeo Therapeutics, Inc. VISTARA BIOSCIENCE LLC GIRISH NALLUR, VISTARA BIOSCIENCE show more Speakers GIRISH NALLUR VISTARA BIOSCIENCE VM Oncology Jay Wu, VM Oncology show more Speakers Jay Wu VM Oncology Vybion, Inc Lee Henderson, Vybion, Inc show more Speakers Lee Henderson Vybion, Inc xCella Biosciences Jennifer Cochran, xCella Biosciences show more Speakers Jennifer Cochran xCella Biosciences Xoc Pharmaceuticals, Inc. Scott Borland, Xoc Pharmaceuticals, Inc. show more Speakers Scott Borland Xoc Pharmaceuticals, Inc. X-Therma Xiaoxi Wei, X-Therma show more Speakers Xiaoxi Wei X-Therma X-Therma Xiaoxi Wei, X-Therma show more Speakers Xiaoxi Wei X-Therma Zenith Epigenetics Donald McCaffrey, Zenith Epigenetics show more Speakers Donald McCaffrey Zenith Epigenetics Zenopharm, LLC Guangdi Wang, Zenopharm, LLC show more Speakers Guangdi Wang Zenopharm, LLC


Session Type

Company Presentation - Presentation Type